Company Overview

Skinvisible, Inc. is a publicly traded micro-cap company historically focused on the development and commercialization of topical drug delivery technologies and dermatology-related products. The company has primarily operated within the biotechnology and dermatological healthcare industries, with an emphasis on enhancing the delivery of active pharmaceutical ingredients through the skin. Its core strategic focus has centered on proprietary transdermal and topical technologies designed to improve efficacy, safety, and patient compliance.

The company’s principal technology has been Invisicare®, a patented polymer-based drug delivery platform intended to enable sustained and controlled topical delivery without skin irritation. Skinvisible was founded in the early 2000s and became publicly listed through a reverse merger. Over time, the company shifted from early-stage research toward licensing and commercialization efforts; however, public disclosures indicate prolonged periods of limited revenue generation and constrained operating activity. Based on available public records, Skinvisible has experienced recurring operational challenges and has not established itself as a scaled commercial enterprise.

Business Operations

Skinvisible’s business operations have historically revolved around the research, development, and potential licensing of Invisicare®-based formulations for pharmaceutical, cosmetic, and medical device applications. Revenue generation, when reported, has primarily been tied to limited licensing arrangements, development agreements, or small-scale product initiatives rather than sustained product sales.

Public filings indicate that the company has maintained minimal domestic operations within the United States, with no verifiable evidence of active large-scale manufacturing or distribution infrastructure. There is no confirmed disclosure of material international operations, major operating subsidiaries, or ongoing joint ventures in recent periods. Data inconclusive based on available public sources regarding current operational scale, active partnerships, or revenue-producing business units.

Strategic Position & Investments

Strategically, Skinvisible has positioned itself as a niche technology owner seeking to monetize its intellectual property through licensing or strategic partnerships rather than direct commercialization. Past disclosures reference efforts to engage pharmaceutical or consumer health companies interested in topical drug delivery enhancements, though no long-term, transformative agreements have been consistently verified.

There is no publicly verified record of significant acquisitions, material capital investments, or ownership of notable subsidiaries or portfolio companies. The company has periodically stated intentions to explore emerging applications of its technology in dermatology and wound care; however, data inconclusive based on available public sources regarding active investments, development pipelines, or participation in emerging healthcare technology sectors.

Geographic Footprint

Skinvisible’s operational footprint has been predominantly domestic, with corporate activities historically based in the United States. Regulatory filings do not substantiate meaningful physical operations, offices, or assets outside the U.S., nor do they confirm sustained international commercial activity.

While the company has referenced the global applicability of its technology in past communications, there is no verified evidence of material market presence, international revenue, or foreign subsidiaries. Data inconclusive based on available public sources regarding any current international operational influence.

Leadership & Governance

Skinvisible has experienced leadership turnover over time, which is common among micro-cap development-stage companies. Governance has been conducted through a small executive team and board structure, as reflected in public filings. The company’s leadership philosophy, based on disclosures, has emphasized capital preservation, intellectual property protection, and strategic optionality through partnerships.

Key executives disclosed in public records include:

• Terry Howlett – Chief Executive Officer
• Robert L. Stewart – Chief Financial Officer
• Richard Golden – Chairman of the Board

No founder-led vision has been consistently emphasized in recent disclosures, and there is limited publicly available information detailing a formalized long-term strategic vision beyond maintaining corporate viability and seeking monetization opportunities for existing assets.